Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing in parallel with the epidemic of obesity and metabolic syndrome. Lifestyle modification is a crucial strategy for the treatment of NAFLD, which can lead to a reduction in liver fat with concomitant weight loss. The use of eHealth technologies is an effective approach to improve health outcomes in patients as they do not have any time and space limitations.
Objective: This study aimed to evaluate published eHealth intervention studies for the improvement of lifestyle modifications among patients with NAFLD and to provide recommendations for future studies.
Methods: We conducted a systematic review and meta-analysis. Five electronic databases (PubMed, Cochrane Central, CINAHL, Embase, and Web of Science) were searched for studies reporting the effect of lifestyle modification intervention using eHealth in patients with NAFLD published from inception to November 3, 2022. Study selection, data extraction, and quality assessment were performed by 3 researchers independently. The quality of included studies was assessed using the Cochrane risk of bias tool and the Risk of Bias Assessment Tool for Nonrandomized Studies.
Results: In total, 2688 records were identified, and 41 full-text articles were assessed. Seven studies were included in the systematic review. The participants of all interventions were 1257 individuals with NAFLD, and the mean age ranged from 38.3 to 57.9 years. The duration of the interventions was 3-24 months, and all interventions were categorized into 3 types: internet-based computers, telephones, and mobile apps. Of these, 4 studies were randomized controlled trials and were included in the meta-analysis: 3 studies for body weight and BMI and 4 studies for alanine aminotransferase (ALT) and aspartate aminotransferase (AST). According to the meta-analysis, clear improvements in BMI (P=.02; 95% CI –1.01 to –0.10), AST (P=.02; 95% CI –1.22 to –0.13), and ALT (P=.01; 95% CI –1.28 to –0.15) were observed in the eHealth intervention as compared with the control groups.
Conclusions: Lifestyle modification interventions using eHealth technologies are significantly effective for BMI, AST, and ALT in patients with NAFLD. Future research should conduct interventions with larger sample sizes and evaluate whether these interventions have sustained benefits, and how we can make these eHealth methods most effective on a large scale.
Nonalcoholic fatty liver disease (NAFLD) is a growing common cause of chronic disease. The global prevalence of NAFLD, which is associated with metabolic syndrome or other chronic diseases such as diabetes, hyperlipidemia, and hypertension, is approximately 33% . NAFLD is historically defined as the presence of >5% hepatic steatosis, excluding secondary causes of hepatic fat accumulation, including excessive alcohol consumption, steatogenic medications, or hereditary disorders [ ]. Clinically, NAFLD encompasses a broad spectrum of liver conditions ranging from simple steatosis or steatohepatitis to hepatic fibrosis, which may lead to cirrhosis, end-stage liver disease, or hepatocellular carcinoma [ ].
NAFLD is usually asymptomatic in the majority of patients and diagnosed by imaging or histology. Since NAFLD is a progressive disease , patients with NAFLD have an increased risk of liver-related complications if not managed. They can develop steatohepatitis, liver fibrosis, cirrhosis, and other related complications, including variceal bleeding, ascites, hepatorenal syndrome, hepatic encephalopathy, and hepatocellular carcinoma [ , ]. In addition, if patients experience these complications, it might result in an increased mortality. However, currently, there is no approved pharmacological agent for treating NAFLD, and therefore, its sustainable management is very important.
The treatment of NAFLD has focused on lifestyle modifications related to dietary habits and physical activity leading to body weight loss [, ]. The current guidelines recommend achieving 7%-10% weight loss as a goal for improving NAFLD conditions [ , ].
Previous studies have conducted lifestyle interventions of various durations and strategies, and several studies have reported positive effects [- ]. However, despite these considerable efforts, changing one’s lifestyle behavior is not easy, and the majority of patients still have not reached the treatment goal, with some difficulties related to sustainability of compliance, proper social support, or constraints on time and place [ - ]. Similar to the COVID-19 pandemic, when on-site medical treatment with clinical health professionals is restricted, a more effective strategy is needed to improve patients’ health outcomes.
eHealth is defined as health services and information delivered or enhanced through the internet and related technologies . As an innovative health care delivery alternative to meet the increasing demand for long-term care of chronic conditions and health care costs [ ], eHealth has been presented as a progressive strategy in various fields. Meta-analyses indicate the positive effects of eHealth services on patients’ health outcomes [ , ]. This is encouraging evidence that eHealth is a beneficial approach to facilitate the modification of unhealthy behavior in patients with NAFLD. However, many eHealth interventions have reported some limitations among patients with other chronic diseases [ ], and only a few studies have reported the effectiveness of lifestyle interventions for NAFLD management. Therefore, health professionals may help identify the effects of eHealth interventions and make decisions regarding intervention development and application [ ].
This systematic review aimed to evaluate the effectiveness of lifestyle modification interventions, using eHealth, in experimental trials involving adults with NAFLD. Additionally, the review compares these eHealth interventions with usual care in terms of key clinical outcome variables.
Protocol and Registration
This systematic review and meta-analysis was conducted using the Cochrane Handbook for Systematic Reviews of Interventions and was reported following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement guidelines . This review was registered in the International Prospective Register of Systematic Reviews (registration number: CRD42021261553). All quantitative studies reporting the use of eHealth interventions were included. Studies were excluded if they did not report outcome measures or were reviews, commentaries, or qualitative studies.
Data Sources and Search Strategy
We conducted a systematic literature search of the PubMed, Cochrane Central, Embase, CINAHL, and Web of Science databases on November 3, 2022. The search strategy included the following keywords as Medical Subject Headings (MeSH) or Embase Subject Headings terms: (“non-alcoholic fatty liver”) AND (“lifestyle modification” OR “diet” OR “exercise” OR “weight loss” OR “body mass index”) AND (“eHealth”). For example, the search strategy in PubMed is presented in. provides the search strategy in all databases.
An example of the search strategy in PubMed.
Nonalcoholic fatty liver
- “non-alcoholic fatty liver” [MeSH Terms] OR “non-alcoholic fatty liver” OR “nonalcoholic fatty liver” OR “non-alcoholic fatty liver” OR “NAFLD” OR “nonalcoholic steatohepatitis” OR “NASH” AND “fatty liver” [MeSH Terms] OR “fatty liver” OR “hepatosteatosis” OR “hepatic steatosis.”
Diet, exercise, weight loss, BMI, and lifestyle modification
- “diet” [MeSH Terms] OR “diet” OR “nutrition” [MeSH Terms] OR “nutrition” OR “food intake” [MeSH Terms] OR “food intake” OR “exercise” [MeSH Terms] OR “exercise” OR “physical activity” OR “weight loss” [MeSH Terms] OR “weight loss” OR “body weight” [MeSH Terms] OR “body weight” OR “body weight change” [MeSH Terms] OR “body weight change” OR “lifestyle modification” OR “lifestyle change” OR “body mass index” [MeSH Terms] OR “body mass index” OR “BMI.”
- “telemedicine” [MeSH Terms] OR “telemedicine” OR “mhealth” OR “mobile health units” [MeSH Terms] OR “mobile health units” OR “cell phone” [MeSH Terms] OR “cell phone” OR “smartphone” [MeSH Terms] OR “smartphone” OR “satellite phone” OR “computers, handheld” [MeSH Terms] OR “computers, handheld” OR “tablet computer” OR “mobile application” OR “mobile app” OR ”apps” OR “eHealth” OR “computers” [MeSH Terms] OR “computers” [All Fields] OR “internet-based intervention” [MeSH Terms] OR “internet-based intervention” OR “internet” OR “internet-based” OR “web-based” OR “text messaging” [MeSH Terms] OR “text messaging” OR “telehealth.”
We included all interventional studies published from inception to November 3, 2022, limited to peer-reviewed articles that were written in English and conducted among humans. We considered the inclusion of literature in this review if it met the following criteria: (1) it dealt with all adults (18 years and older) diagnosed with NAFLD using sonography or transient elastography (FibroScan, Echosens); (2) any eHealth interventions for lifestyle modification related to diet or physical activity, delivered through an electronic device with internet connectivity or wireless capacity, were used; and (3) outcomes were reported as any quantifiable measure for evaluating the effect of lifestyle modification (body weight, BMI, alanine aminotransferase [ALT], or aspartate aminotransferase [AST]).
The exclusion criteria were as follows: (1) if patients with NAFLD were not the main participants, (2) if NAFLD was not the primary diagnosis, (3) if interventions were only targeted at patients with NAFLD, and (4) if only eHealth techniques were used for evaluating the outcomes.
Study citations were imported and compiled into reference management software (Endnote X9.2; Clarivate Analytics) for selection. Studies were screened and selected by 3 reviewers (JC, OYK, and YJ). For the initial search, after removing duplicates, 2 researchers (JC and OYK) independently screened the titles and abstracts of the studies identified from 5 electronic databases to remove irrelevant studies, using eligibility assessment lists. In the second phase, the researchers checked the study types of all the remaining studies, and the full texts of potentially relevant articles were retrieved. Any disagreements or discrepancies between the 2 authors (JC and OYK) regarding the inclusion of studies were resolved through discussion with a third reviewer (YJ).
Two researchers (JC and OYK) extracted and cross-checked the data independently. The following information was extracted from each selected study: author, year of publication, study location, intervention and control groups (age, sex, and sample size), details about intervention and control (device, intervention and control type, intervention content, and follow-up duration), and relevant outcomes and results. If the studies reported that data were insufficient for meta-analysis, the lacking data were requested from the corresponding authors. All the researchers checked the extracted data for consistency. Discrepancies were resolved through discussions.
Data Synthesis and Analysis
Descriptive analyses of the data were performed, and the findings were synthesized based on the category of outcomes, intervention type and content, and its effect. The primary outcomes of this review were weight, BMI, and liver enzyme levels. When an original study reported only the total sample size of the follow-up data without the number of each control and intervention group, we estimated the sample size of each group using pooled standard deviation formula with pooled SD of each group and 95% CI .
Meta-analysis of the extracted data was conducted using the Review Manager of the Cochrane Collaboration (RevMan 5.3, Cochrane Organization). Standardized mean differences (SMDs) and corresponding 95% CIs were computed as between-group differences in means divided by pooled SDs with Hedges correction . The Cochrane Handbook states that the pooled SMDs are equal to the effect size.
Heterogeneity within studies was calculated using the I2 heterogeneity degree, wherein 20%, 50%, and 75% were considered indicative of low, medium, and high heterogeneity, respectively . We used a fixed effect model for meta-analyses. If heterogeneity, as measured by I2 heterogeneity degree, was greater than 50% and P<.1, we performed random-effects analysis.
Risk of Bias Assessment
The quality of included studies was assessed by using the Cochrane Collaboration Risk of Bias Tool (RoB II) for included randomized controlled trials (RCT) . For nonrandomized controlled studies, the risk of bias assessment tool for nonrandomized studies developed by the Korean National Evidence-Based Healthcare Collaborating Agency was used to evaluate the risk of bias [ ]. Two researchers (JY and OYK) independently completed the bias assessment, and any disagreement was resolved through consultation with a third researcher (YJ).
For RCTs, the following criteria were considered: (1) the randomization process, (2) deviations from intended interventions, (3) missing outcome data, (4) measurement of the outcome, and (5) selection of the reported result. Each domain was evaluated using the Cochrane risk ratings of “low,” “high,” and “some concerns.” The criteria considered for the quasi-experimental trial included (1) the selection of participants, (2) confounding variables, (3) the measurement of exposure, (4) blinding of the outcome assessments, (5) incomplete outcome data, and (6) selective outcome reporting. Risk ratings of “low,” “high,” and “unclear” were assigned for each bias.
Our initial search identified 2688 records from 5 relevant database searches (). After excluding duplicates, 2270 articles were screened by title and abstract, resulting in the exclusion of a further 2229. We assessed the full text of 41 potentially eligible papers, and 8 of those met the inclusion criteria. Of those, the studies by Pfirrmann et al [ ] and Huber et al [ ] used the same intervention program and study population, which was taken into account. Seven intervention studies [ , - ] were consequently included in this review. All included studies were clinical trials: 4 were RCTs [ - ] and 3 were non-RCTs [ , , ]. All 7 studies were included in the descriptive synthesis. From among these, 4 studies that were conducted using random allocation were included in the meta-analysis.
Characteristics of Included Studies
The characteristics of the included studies are summarized in. The studies were published during 2016-2022 in 6 geographical regions (China, Germany, Iran, Italy, Singapore, and the United States).
This review encompassed 1257 participants [, - ]; 498 (39.6%) were recruited from gastrointestinal clinics affiliated to a hospital [ - , ] and 759 (60.4%) were enlisted from either the center of Metabolic Diseases and Clinical Dietetics or Sports Medicine, which serves as the second-level center [ , ]. The average age of the participants in the studies ranged from 38.3 to 57.9 years, and 65.1% (818/1257) were male. One study recruited only male participants [ ]. The duration of the intervention ranged from 3 to 24 months. The mean sample size was 180 individuals, the lowest number being 30, and the highest 716.
The majority of participants had NAFLD, regardless of whether they were overweight, obese, or diabetic. However, Lim et al  only recruited patients diagnosed with NAFLD who had a BMI ≥ 23 kg/m2.
|Study||Country||Study design||Study participants, sample size (n)||Participants age (years), mean (SD)||Duration (months)|
|Dong et al , 2016||China||RCTa||24|
|Fard et al , 2016||Iran||RCT||3|
|Axley et al , 2017||United States||RCT||6|
|Lim et al , 2020||Singapore||RCT||6|
|Mazzotti et al , 2018||Italy||Non-RCT||3|
|Pfirrmann et al , 2019||Germany||Non-RCT||3|
|Tincopa et al , 2022||United States||Non-RCT||6|
aRCT: randomized controlled trial.
bNAFLD: nonalcoholic fatty liver disease.
cIG: intervention group.
dCG: control group.
The characteristics of the interventions are presented in. Of the included 7 studies, 3 studies [ , , ] provided professional counseling of diet and physical activity to both intervention and control group. The intervention group additionally administrated a contact-free visit or web-based contact by health professionals for providing health guidance or following up on recommended information. Two interventions [ , ] operated additional intervention components only to the intervention group, while providing standard care for liver disease in the clinic to the control group. Two studies mainly provided intervention on exercise to the intervention group [ ], and one of the studies included nutritional assessment [ ].
All studies measured changes in body weight, BMI, and liver enzymes [, - ]. Five of the studies used weight loss as the main outcome [ , , , , ], and 1 study reported liver enzymes as the primary outcome [ ] and 1, a pilot study, assessed drop and completion rates [ ]. Six studies measured the body weight of participants by trained personnel using standardized procedures and equipment, but 1 study did not report the measurement methods [ ]. Five of the included studies reported that the effect was statistically significant in the intervention group compared to the control group. One study that used a single-arm design showed significant differences in body weight and BMI compared to baseline [ ].
|Study||Description of the study group||Intervention effect|
|Intervention group||Control group|
|Dong et al , 2016||Weight: +a (IGb), BMI: + (IG, CGc), ACd: + (IG), ALTe: + (IG), ASTf: −g, NAFLD-FSh: + (IG, CG), liver steatosis grade: + (IG, CG)|
|Fard et al , 2016||Weight: + (IG), BMI: + (IG), ALT: + (IG), AST: + (IG)|
|Axley et al , 2017||Weight: + (IG), BMI: + (IG), ALT: + (IG), AST: + (IG), HDLi: −, TGj: + (IG)|
|Lim et al , 2020||Weight: + (IG), BMI: + (IG), Waist circumference: + (IG, CG), ALT: + (IG), AST: + (IG)|
|Mazzotti et al , 2018||Weight: + (IG), 10% weight loss: −, Waist circumference: + (IG), GGTk: + (IG), ALT: + (IG)|
|Pfirrmann et al , 2019||Weight: +, body fat: +|
|Tincopa et al ||Weight: −, BMI: −, Liver fat: −, Waist circumference: +, HDL: +, LDL: +, TG: +, HbA1cl: +|
bIG: intervention group.
cCG: control group.
dAC: abdominal circumference.
eALT: alanine aminotransferase.
fAST: aspartate aminotransferase.
hNAFLD-FS: nonalcoholic fatty liver disease fibrosis score.
iHDL: high-density lipoprotein.
kGGT: gamma-glutamyl transferase.
lHbA1c: hemoglobin A1c.
Intervention Delivery and Frequency
This review classified the intervention features of lifestyle modification of NAFLD into 8 components: initial assessment, information on NAFLD, education related to disease or healthy lifestyle, goal setting, counseling of diet and physical activity, reminders for self-management behaviors, feedback, and interactions as social support (). Each intervention used at least 4 components. All studies conducted initial assessments of participants’ physical condition, laboratory data, or self-management [ , - ], and 6 studies set individual goals [ , , , - ]. Six studies provided education on a healthy diet and physical activity for weight loss [ , , - ]. One study provided biweekly group exercise training at a sports center [ ]. Counseling with health guidance or feedback on diet and exercise logs was conducted between participants and health professionals in 5 of the studies, using phone calls [ , ], web discussion boards [ ], regular messages [ ], and emails [ ] for goal setting, behavior change, and encouragement. Two studies issued reminders to log meal intakes every day and weight twice a week [ , ]. Three studies provided support systems to bolster user motivation using chat channels and to improve social support and adherence by using a discussion board [ , , ]. Two interventions were made by telephone to follow-up on guidance of the healthy diets and physical activities for NAFLD self-management [ , ], and 1 intervention used SMS text messages that generated automated or customized messages to provide education and to encourage participants [ ]. Only one intervention used interactive mobile phone apps [ ]. Two studies were conducted using web-based platforms that could accommodate group sessions and also provide individual counsel [ , ].
The intervention frequency varied according to the contents of each study. Most messages for facilitating lifestyle behaviors or motivational information were sent daily [, ], and education on diet and exercise was provided 1-7 times per week. Feedback about the adherence or performance of participants was provided with various frequencies using a web platform, phone, or mobile phone.
|Study||Delivery mode||Component of intervention||Frequency|
|Dong et al , 2016||Telephone||✓||✓||—i||✓||✓||—||✓||—||Every 3 months|
|Fard et al , 2016||Telephone||✓||✓||✓||—||✓||—||✓||—||1-3 times per week|
|Axley et al , 2017||SMS text message||✓||✓||✓||✓||—||—||✓||—||Daily|
|Lim et al , 2020||Mobile app||✓||✓||✓||✓||✓||✓||✓||✓||Daily|
|Mazzotti et al , 2018||Web-based platform||✓||✓||✓||✓||✓||—||—||✓||Weekly|
|Pfirrmann et al , 2019||Web-based platform||✓||✓||✓||✓||✓||✓||✓||✓||5 sessions per week|
|Tincopa et al ||Mobile technology-based||✓||—||✓||✓||—||—||✓||—||Weekly|
dGS: goal setting.
Meta-analysis of Weight, BMI, ALT, and AST
Out of 7 studies, 4 were included in the meta-analysis [- ]. Regarding the 3 studies that have been excluded, 1 study did not apply a random allocation [ ] and 2 were conducted with a single arm [ , ]. Four studies reported body weight, BMI, ALT, and AST as outcomes. However, 1 study did not report the SD of body weight and BMI. We tried to contact the authors for updating the insufficient data but did not get any response and excluded the study of the relevant analyses [ ]. As a result, 3 interventions were shown in the forest plot of body weight and BMI [ , , ], and 4 interventions for ALT and AST [ - ].
As shown in, the estimated SMD of body weight between the intervention and control groups was not significant as 0.45 (95% CI 0.91 to 0.01; P=.05), with a moderate level of heterogeneity (I2=72%). There was a statistically significant difference in BMI (SMD −0.56, 95% CI 1.01 to 0.10; P=.02) between the intervention and control groups, as shown in the forest plot, with a moderate level of heterogeneity (I2=72%; ). Significant differences were also found between the 3 groups measuring the effects of lifestyle modification interventions on ALT (SMD 0.67, 95% CI 1.22 to 0.13; P=.02; ) and AST (SMD −0.72, 95% CI −1.28 to −0.15; P=.01; ). There was a high level of heterogeneity between the studies (I2=83%; I2=84%). provides all results of the meta-analysis.
Risk of Bias
The details of the 4 RCTs’ risk of bias are summarized in[ - ]. Overall, the majority of studies were classified as having a low risk of bias across all main sources of bias and adopted a randomization process, measurement, and reporting of the outcome. Among all studies, 1 RCT identified “some concerns” because of the assessment of the probability of deviations from intended interventions [ ]. The risk of bias assessments for the 3 non-RCTs is presented in [ , , ]. All interventions were found to be “Low risk,” except for “Incomplete outcome data,” for which bias was found in 2 studies [ , ].
This systematic review summarized the results for the effectiveness of eHealth interventions for lifestyle modifications in body weight, BMI, ALT, and AST among adult patients with NAFLD. All the interventions were published between 2016 and 2022. This shows that eHealth technology is not yet widely applied in NAFLD treatment interventions. This study is therefore significant, as it is the first review to identify the effect of eHealth-enabled interventions for supporting sustainable NAFLD management.
Interventions using eHealth for NAFLD were beneficial at achieving weight loss and effective in improving BMI according to the findings of our systematic review and meta-analysis. The NAFLD guideline states that weight loss is the primary goal in the treatment of NAFLD, which leads to reduced liver fat . Although the eHealth interventions were not statistically effective for weight loss, the result showed a trend, which could be helpful for weight loss. The small differences in weight reduction or BMI between intervention and control groups may occur as a placebo effect under natural circumstances [ ]. The results of this review are consistent with the recommendations in the guidelines and are similar to those of previous studies that verified the effect of eHealth interventions on weight loss or BMI in other populations [ , ].
The eHealth interventions to improve BMI were effective when conducted for 3 months or longer and ranged in duration from 3 to 24 months. However, in a meta-analysis of BMI, 2 of the 3 studies that were performed for 6 months were more effective than those that were performed for 24 months. Additionally, the frequency of contact using the intervention component delivered to participants varied from daily [, ] to 1-3 times a week [ ], and every 3 months [ ]. The meta-analysis shows that the effect of interventions on BMI was better when delivered daily than was the case with longer intervals. Although the optimal contact frequency of participants with health professionals in the achievement of each intervention is unclear, frequent contact using eHealth may help achieve weight loss among this population. However, several frequent contacts will displease patients and require more resources in terms of time and manpower. Therefore, further reviews of optimal and cost-effective contact frequencies in eHealth should be performed to improve health outcomes in this population.
Lifestyle modification approaches use various intervention contents, such as assessment of participants’ lifestyle behaviors, information, education, goal setting, counseling, and feedback. In particular, most of the interventions included in the meta-analysis to examine the effectiveness of outcomes consisted of the assessment of health conditions, information on disease treatment or healthy behavior, goal setting of the behavior, and feedback on performance or self-monitoring. The effectiveness of these strategies in promoting changes in unhealthy lifestyle behaviors has been presented in previous eHealth interventions on weight management in other diseases [, ]. It is well known that NAFLD has no disease-specific symptoms unless it progresses to severe liver diseases such as liver cirrhosis. Therefore, patients with NAFLD may lack motivation for or adherence to disease management. Interventions using eHealth with various contents would motivate their behavior and ultimately enhance sustainable NAFLD management.
Furthermore, the results of this review show that lifestyle modification interventions enabled eHealth to significantly improve biomarkers related to liver health. Some studies evaluating improvements in liver histology resulting from weight loss through lifestyle modification have reported significantly reduced ALT and AST [- ], and identified combinations of the effective level of diet and exercise to achieve the outcome. However, these results were not consistent in all of the related studies [ - ], and it is known that generally, the levels of liver enzymes are not elevated in patients with simple steatosis [ ]. Although the significance levels of liver enzymes were moderate or above in this meta-analysis, further studies are needed to analyze the biomarkers that clinically indicate the improvement of NAFLD.
Lifestyle modification, in the absence of pharmacological treatment, is important for patients with NAFLD to treat their health condition; it should be continued with a multidisciplinary team approach including health care professionals, dietitians, and exercise experts to motivate and guide these patients. This study highlights that eHealth technology-based lifestyle modifications may help not only with weight loss but also in improving unhealthy liver conditions through the control of liver enzymes.
Strengths and Limitations of the Study
This study included clinical trials of lifestyle modification programs delivered by eHealth for the self-management of NAFLD and the first systematic review that analyzed the characteristics and effects using meta-analysis. Additionally, the results add to the existing knowledge on the improvement of NAFLD management.
This systematic review and meta-analysis have some limitations. First, the number of analyzed studies was small. This may reduce the generalizability of the findings and make it difficult to recommend the use of eHealth in clinical trials. Second, self-reporting of compliance related to diet and exercise potentially has a probability of recall and social desirability bias. This bias would affect the effectiveness of the outcomes. Lastly, the duration of the included studies ranges from 3 to 24 months. Thus, more evidence is needed to confirm the duration to improve outcomes of eHealth interventions in this population.
This systematic review and meta-analysis aimed to identify and evaluate the effectiveness of eHealth interventions on lifestyle modifications in patients with NAFLD. The results demonstrated that an eHealth intervention was effective in improving body weight, BMI, and ALT and AST levels among these participants. In conclusion, eHealth technology has proven to be a potentially useful intervention strategy for modification of diet and exercise habits and will be an important facilitator to improve self-management skills for patients with NAFLD.
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (2017R1D1A1B04032264) and the Brain Korea 21 FOUR project funded by the National Research Foundation of Korea, Yonsei University College of Nursing. The sources of funding had no role in the design or conduct of the study or decision to submit the manuscript for publication.
OYK and YJ developed the research question. OYK, JC, and YJ participated in screening, extraction, data tabulation, and quality assessment. OYK and YJ analyzed the data, interpreted the results, and drafted the manuscript. All authors have read and contributed to the final manuscript.
Conflicts of Interest
Search strategy.DOCX File , 29 KB
Meta-analysis, forest plot, and quality assessment.DOCX File , 745 KB
- Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021;S1542-3565(21):01276-3. [CrossRef]
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005-2023. [CrossRef]
- Ekstedt M, Nasr P, Kechagias S. Natural history of NAFLD/NASH. Curr Hepatol Rep 2017;16(4):391-397. [CrossRef]
- McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62(5):1148-1155. [CrossRef]
- Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65(1):310-335. [CrossRef] [Medline]
- Muthiah MD, Cheng Han N, Sanyal AJ. A clinical overview of non‐alcoholic fatty liver disease: a guide to diagnosis, the clinical features, and complications- what the non‐specialist needs to know. Diabetes Obes Metab 2022;24(suppl 2):3-14. [CrossRef]
- Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55(4):885-904. [CrossRef]
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts 2016;9(2):65-90. [CrossRef]
- Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013;6(4):249-259. [CrossRef]
- Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2013;59(3):536-542. [CrossRef]
- Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012;57(1):157-166. [CrossRef]
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149(2):367-378.e5. [CrossRef]
- Thomas N, Alder E, Leese G. Barriers to physical activity in patients with diabetes. Postgrad Med J 2004;80(943):287-291 [FREE Full text] [CrossRef]
- Whitsett M, VanWagner LB. Physical activity as a treatment of non-alcoholic fatty liver disease: a systematic review. World J Hepatol 2015;7(16):2041-2052 [FREE Full text] [CrossRef]
- Eysenbach G. What is e-health? J Med Internet Res 2001;3(2):e20 [FREE Full text] [CrossRef] [Medline]
- Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009;374(9696):1196-1208. [CrossRef]
- Wang Y, Xue H, Huang Y, Huang L, Zhang D. A systematic review of application and effectiveness of mHealth interventions for obesity and diabetes treatment and self-management. Adv Nutr 2017;8(3):449-462. [CrossRef]
- Stratton E, Lampit A, Choi I, Calvo RA, Harvey SB, Glozier N. Effectiveness of eHealth interventions for reducing mental health conditions in employees: a systematic review and meta-analysis. PLoS One 2017;12(12):e0189904. [CrossRef]
- Wang Y, Min J, Khuri J, Xue H, Xie B, A Kaminsky L, et al. Effectiveness of mobile health interventions on diabetes and obesity treatment and management: systematic review of systematic reviews. JMIR Mhealth Uhealth 2020;8(4):e15400 [FREE Full text] [CrossRef] [Medline]
- Metzger MJ, Flanagin AJ. Using web 2.0 technologies to enhance evidence-based medical information. J Health Commun 2011;16(suppl 1):45-58 [FREE Full text] [CrossRef]
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 2021;134:103-112. [CrossRef]
- Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester, UK: John Wiley & Sons; 2019.
- Kim S, Park J, Seo H, Lee Y, Jang B, Son H, et al. NECA's Guidance for Undertaking Systematic Reviews and Meta-analyses for Intervention. Seoul: National Evidence-based Healthcare Collaborating Agency; 2011.
- Pfirrmann D, Huber Y, Schattenberg JM, Simon P. Web-based exercise as an effective complementary treatment for patients with nonalcoholic fatty liver disease: intervention study. J Med Internet Res 2019;21(1):e11250 [FREE Full text] [CrossRef] [Medline]
- Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, et al. Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol Ther 2019;50(8):930-939. [CrossRef]
- Axley P, Kodali S, Kuo YF, Ravi S, Seay T, Parikh NM, et al. Text messaging approach improves weight loss in patients with nonalcoholic fatty liver disease: a randomized study. Liver Int 2018;38(5):924-931. [CrossRef]
- Dong F, Zhang Y, Huang Y, Wang Y, Zhang G, Hu X, et al. Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial. Sci Rep 2016;6:36783. [CrossRef]
- Fard SJ, Ghodsbin F, Kaviani MJ, Jahanbin I, Bagheri Z. The effect of follow up (telenursing) on liver enzymes in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery 2016;4(3):239-246 [FREE Full text] [Medline]
- Lim SL, Johal J, Ong KW, Han CY, Chan YH, Lee YM, et al. Lifestyle intervention enabled by mobile technology on weight loss in patients with nonalcoholic fatty liver disease: randomized controlled trial. JMIR Mhealth Uhealth 2020;8(4):e14802 [FREE Full text] [CrossRef] [Medline]
- Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, et al. An internet-based approach for lifestyle changes in patients with NAFLD: two-year effects on weight loss and surrogate markers. J Hepatol 2018;69(5):1155-1163. [CrossRef]
- Tincopa MA, Lyden A, Wong J, Jackson EA, Richardson C, Lok AS. Impact of a pilot structured mobile technology based lifestyle intervention for patients with nonalcoholic fatty liver disease. Dig Dis Sci 2022;67(2):481-491. [CrossRef]
- Ng CH, Xiao J, Lim WH, Chin YH, Yong JN, Tan DJH, et al. Placebo effect on progression and regression in NASH: evidence from a meta‐analysis. Hepatology 2022;75(6):1647-1661. [CrossRef]
- Lau Y, Chee DGH, Chow XP, Cheng LJ, Wong SN. Personalised eHealth interventions in adults with overweight and obesity: a systematic review and meta-analysis of randomised controlled trials. Prev Med 2020;132:106001. [CrossRef]
- Wu X, Guo X, Zhang Z. The efficacy of mobile phone apps for lifestyle modification in diabetes: systematic review and meta-analysis. JMIR Mhealth Uhealth 2019;7(1):e12297 [FREE Full text] [CrossRef] [Medline]
- Martin CK, Gilmore LA, Apolzan JW, Myers CA, Thomas DM, Redman LM. Smartloss: a personalized mobile health intervention for weight management and health promotion. JMIR Mhealth Uhealth 2016;4(1):e18. [CrossRef]
- Ryan K, Dockray S, Linehan C. A systematic review of tailored eHealth interventions for weight loss. Digit Health 2019;5:2055207619826685. [CrossRef]
- Kani AH, Alavian SM, Esmaillzadeh A, Adibi P, Azadbakht L. Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: a parallel randomized trial. Nutrition 2014;30(7-8):814-821. [CrossRef]
- Razavi Zade M, Telkabadi MH, Bahmani F, Salehi B, Farshbaf S, Asemi Z. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial. Liver Int 2016;36(4):563-571. [CrossRef]
- St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol 2009;24(3):399-407. [CrossRef]
- Rodrŕguez-Hernández H, Cervantes-Huerta M, Rodrŕguez-Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Ann Hepatol 2011;10(4):486-492. [CrossRef]
- Al-Jiffri O, Al-Sharif FM, Abd El-Kader SM, Ashmawy EM. Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver. Afr Health Sci 2013;13(3):667-672. [CrossRef]
- Balducci S, Cardelli P, Pugliese L, D’Errico V, Haxhi J, Alessi E, Italian Diabetes Exercise Study (IDES) Investigators. Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes: the italian diabetes exercise study (IDES). Diabetes Res Clin Pract 2015;109(2):355-363. [CrossRef]
- Keating SE, Hackett DA, Parker HM, O’Connor HT, Gerofi JA, Sainsbury A, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol 2015;63(1):174-182 [FREE Full text] [CrossRef]
- Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol 2014;20(15):4382-4392. [CrossRef]
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73-84. [CrossRef] [Medline]
|ALT: alanine aminotransferase|
|AST: aspartate aminotransferase|
|MeSH: Medical Subject Headings|
|NAFLD: nonalcoholic fatty liver disease|
|RCT: randomized controlled trial|
Edited by G Eysenbach; submitted 01.03.22; peer-reviewed by CH Ng, P Simon, K Fitzner; comments to author 30.08.22; revised version received 20.11.22; accepted 18.12.22; published 23.01.23Copyright
©Oh Young Kwon, Jin-young Choi, Yeonsoo Jang. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 23.01.2023.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.